Last reviewed · How we verify

NCT04706650

Exercise Capacity, Cardiovascular Risk Factors and Disease-related Variables in Axial Spondyloarthritis

Completed Last updated 13 January 2021
What this trial tests

trial in Exercise Capacity in 76 participants. Completed in 15 October 2014.

Timeline
15 May 2014
Primary endpoint
15 October 2014
15 October 2014

Quick facts

Lead sponsorMuğla Sıtkı Koçman University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment76
Start date15 May 2014
Primary completion15 October 2014
Estimated completion15 October 2014

Conditions studied

Sponsor

Muğla Sıtkı Koçman University

Who can join

Adults 18 to 70, any sex, with Exercise Capacity or Axial Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to study the associations between exercise capacity and cardiovascular (CV) risk factors in axial spondyloarthritis (axSpA) patients and to determine possible relationships with disease-related variables. Thirty eight patients and 38 controls were recruited in our cross-sectional controlled study. Comprehensive systemic and musculoskeletal examinations were carried out in both of the groups. Cardiovascular risk profile data, ASDAS-CRP, 10-year CV event risk, physical activity levels (IPAQ) were recorded. A maximal treadmill exercise test by Bruce protocol was administered to all participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Exercise Capacity

Currently open trials in the same condition.

Other Muğla Sıtkı Koçman University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04706650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing